CY1115251T1 - Θεραπεια λευχαιμιας ανθεκτικης σε ιματινιμπη χρησιμοποιωντας 4-αμινοκινολινο-3-καρβονιτριλια - Google Patents

Θεραπεια λευχαιμιας ανθεκτικης σε ιματινιμπη χρησιμοποιωντας 4-αμινοκινολινο-3-καρβονιτριλια

Info

Publication number
CY1115251T1
CY1115251T1 CY20141100395T CY141100395T CY1115251T1 CY 1115251 T1 CY1115251 T1 CY 1115251T1 CY 20141100395 T CY20141100395 T CY 20141100395T CY 141100395 T CY141100395 T CY 141100395T CY 1115251 T1 CY1115251 T1 CY 1115251T1
Authority
CY
Cyprus
Prior art keywords
carbonitrile
aminokinolino
therapy treatment
imatinib
leukemia therapy
Prior art date
Application number
CY20141100395T
Other languages
Greek (el)
English (en)
Inventor
Becker Hewes
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39639071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115251(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of CY1115251T1 publication Critical patent/CY1115251T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CY20141100395T 2007-06-01 2014-06-03 Θεραπεια λευχαιμιας ανθεκτικης σε ιματινιμπη χρησιμοποιωντας 4-αμινοκινολινο-3-καρβονιτριλια CY1115251T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93265007P 2007-06-01 2007-06-01
EP12160638.8A EP2478905B1 (en) 2007-06-01 2008-05-30 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles

Publications (1)

Publication Number Publication Date
CY1115251T1 true CY1115251T1 (el) 2017-01-04

Family

ID=39639071

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20141100395T CY1115251T1 (el) 2007-06-01 2014-06-03 Θεραπεια λευχαιμιας ανθεκτικης σε ιματινιμπη χρησιμοποιωντας 4-αμινοκινολινο-3-καρβονιτριλια
CY20211100693T CY1124391T1 (el) 2007-06-01 2021-08-03 Θεραπεια ανθεκτικης σε ιματινιμπη χρονιας μυελογενους λευχαιμιας που εχει τη μεταλλαξη 1457t>c στο bcrabl γονιδιο χρησιμοποιωντας την ενωση μποσουτινιμπη

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20211100693T CY1124391T1 (el) 2007-06-01 2021-08-03 Θεραπεια ανθεκτικης σε ιματινιμπη χρονιας μυελογενους λευχαιμιας που εχει τη μεταλλαξη 1457t>c στο bcrabl γονιδιο χρησιμοποιωντας την ενωση μποσουτινιμπη

Country Status (23)

Country Link
US (1) US11103497B2 (cg-RX-API-DMAC7.html)
EP (4) EP2777704A3 (cg-RX-API-DMAC7.html)
JP (3) JP5888853B2 (cg-RX-API-DMAC7.html)
KR (1) KR101493543B1 (cg-RX-API-DMAC7.html)
CN (1) CN101686973B (cg-RX-API-DMAC7.html)
AU (1) AU2008260070B9 (cg-RX-API-DMAC7.html)
BR (1) BRPI0812355A2 (cg-RX-API-DMAC7.html)
CA (3) CA2688467C (cg-RX-API-DMAC7.html)
CL (1) CL2008001577A1 (cg-RX-API-DMAC7.html)
CY (2) CY1115251T1 (cg-RX-API-DMAC7.html)
DK (2) DK2478905T3 (cg-RX-API-DMAC7.html)
ES (2) ES2881391T3 (cg-RX-API-DMAC7.html)
HU (1) HUE055524T2 (cg-RX-API-DMAC7.html)
IL (1) IL202407A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009013069A (cg-RX-API-DMAC7.html)
PA (1) PA8782301A1 (cg-RX-API-DMAC7.html)
PL (2) PL3002009T3 (cg-RX-API-DMAC7.html)
PT (2) PT3002009T (cg-RX-API-DMAC7.html)
RU (1) RU2464026C2 (cg-RX-API-DMAC7.html)
SI (2) SI3002009T1 (cg-RX-API-DMAC7.html)
TW (1) TW200908982A (cg-RX-API-DMAC7.html)
WO (1) WO2008150957A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200908480B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2777704A3 (en) * 2007-06-01 2015-01-21 Wyeth LLC Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles
JP6026441B2 (ja) 2011-03-04 2016-11-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited キナーゼ阻害剤としてのアミノキノリン
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
CN105143208B (zh) 2013-02-21 2017-09-26 葛兰素史密斯克莱知识产权发展有限公司 作为激酶抑制剂的喹唑啉
KR101733665B1 (ko) * 2015-05-06 2017-05-10 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 F1 또는 Rg3을 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물
JP2022544700A (ja) * 2019-08-22 2022-10-20 バイオヘイブン・セラピューティクス・リミテッド 筋萎縮性側索硬化症および関連障害の治療のためにtdp-43に結合する分子
CN115944636A (zh) * 2022-11-01 2023-04-11 华南师范大学 博舒替尼在抑制i-motif结构上的应用
EP4746884A2 (en) * 2023-07-21 2026-05-27 Icahn School of Medicine at Mount Sinai G9a/glp inhibitors and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
CA2434526C (en) * 2001-01-25 2011-11-01 Bristol Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
EP2341133A1 (en) 2001-10-05 2011-07-06 Novartis AG Mutated Abl kinase domains
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20050010780A1 (en) * 2003-07-09 2005-01-13 Kane John Richard Method and apparatus for providing access to personal information
CA2543163A1 (en) 2003-11-06 2005-05-26 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
TW200724548A (en) 2005-04-25 2007-07-01 Pfizer Antibodies to myostatin
AU2006247322A1 (en) * 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
AU2006270187A1 (en) 2005-07-15 2007-01-25 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant SRC kinase polypeptides
KR101135220B1 (ko) 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
WO2007056177A2 (en) * 2005-11-04 2007-05-18 Bristol-Myers Squibb Pharma Company T315a and f317i mutations of bcr-abl kinase domain
EP2777704A3 (en) * 2007-06-01 2015-01-21 Wyeth LLC Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles

Also Published As

Publication number Publication date
EP2478905A2 (en) 2012-07-25
HUE055524T2 (hu) 2021-11-29
RU2009144128A (ru) 2011-07-20
CY1124391T1 (el) 2022-07-22
EP3002009B1 (en) 2021-07-07
CN101686973A (zh) 2010-03-31
JP2014111629A (ja) 2014-06-19
RU2464026C2 (ru) 2012-10-20
CA2964162A1 (en) 2008-12-11
EP3002009A3 (en) 2016-07-06
AU2008260070B2 (en) 2011-08-18
DK2478905T3 (da) 2014-06-30
IL202407A0 (en) 2010-06-30
EP2777704A2 (en) 2014-09-17
PT3002009T (pt) 2021-08-02
AU2008260070A1 (en) 2008-12-11
EP2478905A3 (en) 2013-01-16
HK1142812A1 (en) 2010-12-17
CN101686973B (zh) 2013-06-19
PA8782301A1 (es) 2009-01-23
WO2008150957A3 (en) 2009-08-06
US11103497B2 (en) 2021-08-31
ZA200908480B (en) 2010-08-25
AU2008260070B9 (en) 2012-01-19
US20080318971A1 (en) 2008-12-25
JP5888853B2 (ja) 2016-03-22
TW200908982A (en) 2009-03-01
PL2478905T3 (pl) 2014-10-31
WO2008150957A2 (en) 2008-12-11
BRPI0812355A2 (pt) 2015-01-27
CA2964162C (en) 2019-12-31
EP2777704A3 (en) 2015-01-21
SI2478905T1 (sl) 2014-07-31
DK3002009T3 (da) 2021-08-02
ES2881391T3 (es) 2021-11-29
CA2688467C (en) 2015-05-12
JP2010529038A (ja) 2010-08-26
EP2152267A2 (en) 2010-02-17
KR101493543B1 (ko) 2015-02-13
JP2016074700A (ja) 2016-05-12
CL2008001577A1 (es) 2008-07-25
PL3002009T3 (pl) 2021-12-13
EP2478905B1 (en) 2014-05-14
CA2868899A1 (en) 2008-12-11
EP3002009A2 (en) 2016-04-06
CA2868899C (en) 2017-06-13
SI3002009T1 (sl) 2021-09-30
PT2478905E (pt) 2014-07-16
KR20100017983A (ko) 2010-02-16
CA2688467A1 (en) 2008-12-11
MX2009013069A (es) 2010-03-17
ES2477567T3 (es) 2014-07-17

Similar Documents

Publication Publication Date Title
LTC2937350I2 (lt) 1'-pakeistieji karba-nukleozidų analogai, skirti antivirusiniam gydymui
EA201171367A1 (ru) Винилиндазолильные соединения
CY1121899T1 (el) Βοριουχα μικρομορια ως αντιφλεγμονωδεις παραγοντες
CY1112151T1 (el) Αγωνιστες τυπου πυριδονης του συζευγμενου με g-πρωτεϊνη υποδοχεα gpr119
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
CY1112595T1 (el) Αμιδοφαινοξυινδαζολια χρησιμα ως αναστολεις του c-met
CY1118523T1 (el) Πεπτιδικες ενωσεις για την θεραπεια του ανθεκτικου status epilepticus
CY2016026I1 (el) Μεθοδος για την θεραπεια του καρκινου με αντισταση στην γεφιτινιβη
CY1117752T1 (el) Τετρακυκλικη ενωση
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
CY1110962T1 (el) Τρικυκλικες ενωσεις και η χρηση τους ως διαμορφωτες του υποδοχεα γλυκοκορτικοειδων
CY1124391T1 (el) Θεραπεια ανθεκτικης σε ιματινιμπη χρονιας μυελογενους λευχαιμιας που εχει τη μεταλλαξη 1457t>c στο bcrabl γονιδιο χρησιμοποιωντας την ενωση μποσουτινιμπη
EA201270049A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
EP2303021A4 (en) COMPOSITIONS FOR CANCER TREATMENT
HUE045430T2 (hu) Ultraibolya fényû kezelõkamra
ECSP11011021A (es) Antagonistas de la via hedgehog de ftalazina disustituida
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
CY1113485T1 (el) Ενωσεις γεφυρωμενης-πιπεριδινης τυπου υποκατεστημενης-κινοξαλινης και οι χρησεις εξ' αυτων
DK2219683T3 (da) Målrettet radioterapi
DK2173337T3 (da) Phosphaplatiner og deres anvendelse i behandlingen af cancer, der er resistent over for cisplatin og carboplatin
DE602008006139D1 (de) Lichtquelle
DK2173831T3 (da) Brøndbehandling
CY1115071T1 (el) Συνδυασμος ο οποιος περιεχει πακλιταξελη για τη θεραπευτικη αντιμετωπιση του καρκινου των ωοθηκων
HUE038563T2 (hu) Rák kezelési eljárás
CY1117674T1 (el) Χρηση παραγωγων των orvinol και thevinol ως θεραπευτικη αγωγη στην καταχρηση αλκοολ και φαρμακων